Evidence map›Paper›PMID 41974183›Full record

ArticleNuklearmedizin. Nuclear medicine2026

Impact assessment of [18F]FDG PET/CT in predicting EGFR gene mutation status in patients with lung adenocarcinoma using recovery coefficient-based correction of semi-quantitative and volume-based PET metrics.

Aleksei Leontev, Angelina Lokhova, Aleksandr Khalimon, Malika Khodzhibekova, Tatyana Lazutina, Gulnara Khamadeeva, Daria Khodakova, Irina Pylova, Vitaly Bobrov, Leila Atakishieva and 7 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Nuklearmedizin. Nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Prognostic value of baselineFrontiers in nuclear medicine · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Aleksei LeontevP. Hertsen Moscow Oncology Research Institute - the branch of the FSBI "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Department of Nuclear Medicine, Russian Federation, Moscow.
Angelina LokhovaP. Hertsen Moscow Oncology Research Institute - the branch of the FSBI "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Department of Nuclear Medicine, Russian Federation, Moscow.
Aleksandr KhalimonP. Hertsen Moscow Oncology Research Institute - the branch of the FSBI "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Department of Nuclear Medicine, Russian Federation, Moscow.
Malika KhodzhibekovaP. Hertsen Moscow Oncology Research Institute - the branch of the FSBI "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Department of Nuclear Medicine, Russian Federation, Moscow.
Tatyana LazutinaP. Hertsen Moscow Oncology Research Institute - the branch of the FSBI "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Department of Nuclear Medicine, Russian Federation, Moscow.
Gulnara KhamadeevaP. Hertsen Moscow Oncology Research Institute - the branch of the FSBI "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Department of Nuclear Medicine, Russian Federation, Moscow.
Daria KhodakovaP. Hertsen Moscow Oncology Research Institute - the branch of the FSBI "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Department of Nuclear Medicine, Russian Federation, Moscow.
Irina PylovaP. Hertsen Moscow Oncology Research Institute - the branch of the FSBI "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Department of Nuclear Medicine, Russian Federation, Moscow.
Vitaly BobrovP. Hertsen Moscow Oncology Research Institute - the branch of the FSBI "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Department of Nuclear Medicine, Russian Federation, Moscow.
Leila AtakishievaN. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - the branch of the FSBI "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Department of Nuclear Medicine, Russian Federation, Moscow.
Natalia KadymovaN. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - the branch of the FSBI "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Department of Nuclear Medicine, Russian Federation, Moscow.
Anastasia NikiforukP. Hertsen Moscow Oncology Research Institute - the branch of the FSBI "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Department of Nuclear Medicine, Russian Federation, Moscow.
Bogdan ShvetsN. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - the branch of the FSBI "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Department of Nuclear Medicine, Russian Federation, Moscow.
Nadezhda VolchenkoP. Hertsen Moscow Oncology Research Institute - the branch of the FSBI "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Department of Nuclear Medicine, Russian Federation, Moscow.
Viktoriya SurkovaP. Hertsen Moscow Oncology Research Institute - the branch of the FSBI "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Department of Nuclear Medicine, Russian Federation, Moscow.
Petr ShatalovP. Hertsen Moscow Oncology Research Institute - the branch of the FSBI "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Department of Nuclear Medicine, Russian Federation, Moscow.
Andrey KaprinP. Hertsen Moscow Oncology Research Institute - the branch of the FSBI "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Department of Nuclear Medicine, Russian Federation, Moscow.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: The aim of this study was to assess the impact of [ Methods: A retrospective multi-center study included 63 patients diagnosed with lung adenocarcinoma who underwent [ Results: No significant difference in tumor lesion maximal diameter, CT volume, evaluated values of PET metrics before and after RC-based correction was found between the EGFR-mutant and wild-type groups (p > 0.05). Conclusion: Observed semi-quantitative and volume-based PET metrics obtained from [

Indexed as

Adenocarcinoma of LungErbB ReceptorsFluorodeoxyglucose F18Lung NeoplasmsPositron Emission Tomography Computed TomographyAdenocarcinomaAgedFemaleHumansMaleMiddle AgedMutationRadiopharmaceuticalsRetrospective StudiesEGFR protein, humanErbB ReceptorsFluorodeoxyglucose F18Radiopharmaceuticals

Identifiers

PMID41974183
PMCPMC13288398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.